CENTO, VALERIA
 Distribuzione geografica
Continente #
NA - Nord America 2.991
AS - Asia 227
EU - Europa 189
SA - Sud America 2
Totale 3.409
Nazione #
US - Stati Uniti d'America 2.988
KR - Corea 122
SG - Singapore 53
CN - Cina 45
UA - Ucraina 38
DE - Germania 27
IE - Irlanda 25
IT - Italia 25
FR - Francia 17
GB - Regno Unito 17
FI - Finlandia 9
SE - Svezia 8
BE - Belgio 5
RU - Federazione Russa 5
PL - Polonia 4
GR - Grecia 3
CA - Canada 2
NL - Olanda 2
VN - Vietnam 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
BR - Brasile 1
CH - Svizzera 1
DM - Dominica 1
EE - Estonia 1
IN - India 1
JP - Giappone 1
KG - Kirghizistan 1
NO - Norvegia 1
SA - Arabia Saudita 1
VA - Santa Sede (Città del Vaticano) 1
Totale 3.409
Città #
Woodbridge 901
Wilmington 731
Houston 707
Fairfield 124
Chandler 112
Ann Arbor 73
Singapore 48
Ashburn 39
Seattle 36
Cambridge 34
Dearborn 23
Dublin 23
Jacksonville 19
Medford 18
New York 13
Rome 11
Beijing 9
Menlo Park 9
Lawrence 8
Palo Alto 8
Nanjing 7
Santa Clara 6
Zhengzhou 6
Brussels 5
Hefei 4
Kraków 4
Kunming 4
Moscow 4
San Diego 4
Shanghai 4
London 3
Milan 3
Munich 3
Phoenix 3
Council Bluffs 2
Dong Ket 2
Engelhard 2
Monte Vista 2
Nanchang 2
Norwalk 2
Wuhan 2
Amsterdam 1
Apo 1
Athens 1
Baotou 1
Billings 1
Boardman 1
Burlington 1
Caserta 1
Cassino 1
Cedarhurst 1
Chicago 1
Clearwater 1
Dubai 1
Groningen 1
Guangzhou 1
Helsinki 1
Indiana 1
Jinan 1
Kherson 1
Mountain View 1
Ningbo 1
Nürnberg 1
Oslo 1
Ottawa 1
Redwood City 1
Riyadh 1
Roseau 1
Simi Valley 1
Stockholm 1
São Paulo 1
Tallinn 1
Tokyo 1
Toronto 1
Verona 1
Totale 3.054
Nome #
HCV-RNA quantification in liver bioptic samples and extrahepatic compartments, using the abbott RealTime HCV assay 443
Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome 419
Optimal efficacy of interferon-free HCV retreatment after protease inhibitors failure in real life. 386
Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning 381
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens 363
Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study 362
Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors 359
Consequences of inaccurate hepatitis C virus genotyping on the costs of prescription of direct antiviral agents in an Italian district 359
Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy 356
Detecting hepatitis B viral amino acid sequence mutations in occult hepatitis B infections via bayesian partition model 16
Temporal trend of drug-resistance and APOBEC editing in PBMC genotypic resistance tests from HIV-1 infected virologically suppressed individuals 10
Totale 3.454
Categoria #
all - tutte 6.355
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.355


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020776 0 0 71 86 84 110 103 74 75 80 46 47
2020/2021448 53 52 52 57 33 49 48 49 12 16 17 10
2021/202297 4 4 0 4 0 12 5 8 11 14 6 29
2022/2023204 30 20 28 28 15 32 9 12 26 0 3 1
2023/202452 7 2 6 0 2 13 0 0 13 0 0 9
2024/202573 10 62 1 0 0 0 0 0 0 0 0 0
Totale 3.454